All content for The exhale podcast, brought to you by Vitalograph is the property of the exhale podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Your host is Mark Russell, Marketing Communications Manager for Vitalograph US, a global leader in respiratory diagnostics.
Annaka Haynes is a nursing student who has had Cystic Fibrosis since she was 6 weeks old. Trikafta developed by Vertex Pharmaceuticals was first approved by the FDA on October 21, 2019. This treatment is a triple combination regimen for cystic fibrosis patients starting at ages 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.
The exhale podcast, brought to you by Vitalograph
Your host is Mark Russell, Marketing Communications Manager for Vitalograph US, a global leader in respiratory diagnostics.
